Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plazomicin versus colistin for CRE bloodstream infection or nosocomial pneumonia
2013-001997-18Phase 3Completed
- Sponsor
- Achaogen, Inc.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of plazomicin and colistimethate sodium in Enterobacterales bloodstream infection, hospital-acquired pneumonia (HAP) and Gram-negative bacterial infection (2 arms), sponsored by Achaogen, Inc. Primary endpoint: All-cause mortality at Day 28. Started Nov 2013; status: completed.
02
Drugs
plazomicincolistimethate sodium
03
Conditions
Enterobacterales bloodstream infectionhospital-acquired pneumonia (HAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on 2013-001997-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001997-18.